title: [Clinical Comparative Study of Two Kind Doses of Bortezomib Combinated with Bisphosphonates for Treating Patients with Multiple Myeloma Ostespathy].
abstract: OBJECTIVE
  To investigate the clinical efficacy and safety of conventional dose and reduction dose of bortezomib in combination with bisphosphonates for treating patients with multiple myeloma ostespathy.
  
  
  METHODS
  A total of 150 patients with multiple myeloma ostespathy were chosen in the period from March 2011 to July 2015 and randomly were divided into 2 groups: A group (75 cases) and B group (75 cases). The patients in A and B groups were treated with conventional dose of bortezomib and reduction dose of bortezomib on the basis of bisphosphonates respectively and the clinical efficacy, the improvement rate of life quality, NRS score, levels of IL-6 and CRP before and after treatment, and the adverse effects of 2 groups were compared.
  
  
  RESULTS
  There was no significant difference in the clinical efficacy between 2 groups (P<0.05). The improvement rate of patients life quality in B group was significantly better than that in A group (P>0.05). There was no significant difference in the NRS score, levels of IL-6 and CRP after treatment between 2 groups (P>0.05). There was no significant difference in the incidence of neutrophil reduction and thrombocytopenia between 2 groups (P<0.05). The incidence of BiPN, nausea and vomiting, herpes zoster and fatigue of B group was significantly lower than that in A group (P<0.05).
  
  
  CONCLUSIONS
  Conventional dose and reduction dose of bortezomib in combination with bisphosphonates for treating patients with multiple myeloma ostespathy possess the same effects, including pain relief and disease progression control; but the reduction dose of bortezomib application can efficiently improve the life quality of patients and reduce the risk of adverse reactions.
authors.affiliation: Department of Hematology, Central Hospital in Xinxiang City, Xinxiang 453000, Henan Province, China. E-mail: maminglun@souhu.com.
authors.forename: Bo
authors.initials: B
authors.lastname: Liang
authors.affiliation: Department of Hematology, Central Hospital in Xinxiang City, Xinxiang 453000, Henan Province, China.
authors.forename: Jun-Jie
authors.initials: JJ
authors.lastname: Yin
authors.affiliation: Department of Hematology, Central Hospital in Xinxiang City, Xinxiang 453000, Henan Province, China.
authors.forename: Zhong-Liang
authors.initials: ZL
authors.lastname: Wang
authors.affiliation: Department of Hematology, Central Hospital in Xinxiang City, Xinxiang 453000, Henan Province, China.
authors.forename: Xin-Rong
authors.initials: XR
authors.lastname: Zhan
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069286:Bortezomib / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D015850:Interleukin-6 / Q000032:analysis; D009101:Multiple Myeloma / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D004164:Diphosphonates; C508600:IL6 protein, human; D015850:Interleukin-6; D000069286:Bortezomib; D002097:C-Reactive Protein